文献速递浆细胞疾病

新诊断骨髓瘤中免疫麻痹的特征及其对老年与近期骨髓瘤试验中无进展生存和总生存的影响

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials.
PubMed 文献 · Leukemia · 2018-06-20

研究测量了5826例英国骨髓瘤试验患者诊断时的免疫抑制状态并评估其对生存的影响。85%患者多克隆免疫球蛋白水平低于正常。近期试验中无免疫麻痹患者的中位总生存比旧试验延长可达3年,而旧试验中延长不足1年。IgM抑制深度与生存相关,感染似乎不是主要机制。

要点

  • 85%新诊断骨髓瘤患者存在多克隆免疫球蛋白低于正常。
  • 近期试验中无免疫麻痹患者中位总生存比旧试验延长可达3年。
  • IgM抑制深度而非IgG或IgA抑制深度对生存有预后价值。

核心结论

  • 免疫麻痹在新诊断骨髓瘤中常见,且对近期试验患者的生存影响更大;IgM抑制深度具有预后价值,感染似乎不是主要机制。

研究设计与样本

  • 研究纳入5826例英国骨髓瘤试验患者,在诊断时测量免疫抑制状态并评估其对生存的影响。

主要发现

  • 多克隆免疫球蛋白水平低于正常者占85%,IgA高于正常者仅0.4%,IgM高于正常者0.2%,IgG无高于正常者。
  • 近期试验中无免疫麻痹患者的中位总生存比旧试验延长可达3年,而旧试验中延长不足1年。
  • IgG、IgA和IgM水平正常患者的中位无进展生存分别延长39%、36%和57%。
  • IgM抑制最严重三分位患者的总生存比最高三分位短0.9年,比IgM水平正常者短2.6年(p = .007)。
  • 多克隆IgM水平低于正常的抑制程度与更差的无进展生存相关(p = .0002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We measured immunosuppression at myeloma diagnosis and assessed the impact on survival in 5826 UK myeloma trial patients. Polyclonal immunoglobulin levels were below normal in 85% of patients and above normal in only 0.4% of cases for IgA, 0.2% for IgM and no cases for IgG. Immunoparesis had a greater impact in recent trials: median overall survival (OS) was up to 3 years longer for patients without immunoparesis compared to the old trials, less than 1 year longer. Median progression-free survival (PFS) was 39%, 36% and 57% longer for patients with normal IgG, IgA and IgM levels, respectively. The depth of IgM suppression, but not the depth of IgG or IgA suppression, was prognostic for survival: the most severely suppressed IgM tertile of patients OS was 0.9 years shorter than those in the top tertile, and 2.6 years shorter than OS of those with normal IgM levels (p = .007). The degree of suppression of polyclonal IgM levels below normal was associated with worse PFS (p = .0002). Infection does not appear to be the main mechanism through which immunoparesis affects survival. We hypothesise that IgM immunoparesis impacts through a combination of being associated with more aggressive disease and reduced immune surveillance against relapse.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Heaney JLJ, Campbell JP, Iqbal G, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018. PMID: 29925902. doi:10.1038/s41375-018-0163-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。